Intangible Assets

COYA’s filings indicate a development-stage biotech model with no established commercialized product franchise, so it lacks the durable brand or regulatory-backed pricing power seen at larger approved-drug peers.

Any intangible value is concentrated in pipeline know-how and clinical/regulatory assets, but these are binary and unproven versus peers with marketed therapies and recurring physician adoption.

Because the company has not yet demonstrated sustained revenue generation or margin durability, its intangible assets do not currently translate into peer-leading retention or pricing power over 5–10 years.

Switching Costs

COYA does not appear to have a commercial customer base with embedded workflows, so there is little evidence of switching costs comparable to peers selling approved therapies into established treatment protocols.

In biotech development, physicians and payers can shift to alternative therapies once available, which keeps retention structurally low versus peers with entrenched prescribing habits or device lock-in.

The absence of recurring product revenue means there is no installed base to create meaningful switching frictions or contract stickiness.

Network Effects

COYA’s business model does not rely on a user-to-user or data-network flywheel, so it lacks the self-reinforcing adoption dynamics that strengthen moat durability in platform peers.

Clinical development can generate evidence accumulation, but that is not a true network effect because it does not create direct peer dependence or compounding customer lock-in.

Relative to peers with large real-world evidence datasets or ecosystem-driven distribution, COYA has no visible network-based advantage.

Cost Advantage

COYA does not show a structural cost advantage because its R&D and clinical trial spending are not lower-cost than peers on a durable basis, and FMP profitability metrics remain negative.

As a small biotech, it lacks scale purchasing power and manufacturing leverage that would support superior unit economics versus larger diversified competitors.

Negative ROIC and minimal asset turnover indicate that current operations are not converting capital into a cost-based advantage over peers.

Efficient Scale

COYA does not operate in a naturally limited market where one or two firms can efficiently serve demand with high barriers to entry, so efficient-scale protection is weak versus peers.

The company faces a crowded therapeutic landscape in which multiple developers can pursue similar indications, limiting any scarcity-based moat.

Without commercial scale, regulatory exclusivity on a marketed product, or infrastructure that would be uneconomic to duplicate, efficient-scale benefits are not yet durable.

Overall Score

COYA’s moat is weak versus peers because it is still a development-stage biotech with no demonstrated commercial franchise, no meaningful switching costs, no network effects, and no durable cost or efficient-scale advantage; any competitive edge remains pipeline-dependent and unproven over a 5–10 year horizon.